Get the Stockscreener App
3.05
0.33%
-0.01
After Hours:
3.12
0.07
+2.30%
Cervomed Inc stock is traded at $3.05, with a volume of 114.76K.
It is down -0.33% in the last 24 hours and down -21.39% over the past month.
CervoMed Inc is a clinical-stage biotechnology company. It is focused on developing treatments for age-related neurologic disorders. The company's product candidate, Neflamapimod, has the potential to treat and improve synaptic dysfunction, the reversible aspect of the underlying disease processes in DLB and certain other neurological disorders.
See More
Previous Close:
$3.06
Open:
$3.09
24h Volume:
114.76K
Relative Volume:
1.64
Market Cap:
$28.24M
Revenue:
$4.01M
Net Income/Loss:
$-26.97M
P/E Ratio:
-1.0267
EPS:
-2.9707
Net Cash Flow:
$-23.45M
1W Performance:
+5.54%
1M Performance:
-21.39%
6M Performance:
-69.32%
1Y Performance:
-63.99%
1-Day Range:
$2.9474
$3.1379
1-Week Range:
$2.8702
$3.27
52-Week Range:
$2.815
$13.13
Cervomed Inc Stock (CRVO) Company Profile
Name
Cervomed Inc
Sector
Industry
Phone
(617) 744-4400
Address
20 PARK PLAZA, BOSTON
Compare CRVO vs VRTX, REGN, ARGX, ALNY, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CRVO
Cervomed Inc
|
3.05 | 28.33M | 4.01M | -26.97M | -23.45M | -2.9707 |
VRTX
Vertex Pharmaceuticals Inc
|
435.93 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
634.62 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
808.43 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Cervomed Inc Stock (CRVO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-18-25 | Initiated | Cantor Fitzgerald | Overweight |
| Mar-13-25 | Upgrade | Chardan Capital Markets | Neutral → Buy |
| Dec-17-24 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Dec-11-24 | Downgrade | Chardan Capital Markets | Buy → Neutral |
| Dec-11-24 | Downgrade | Morgan Stanley | Overweight → Underweight |
| Dec-10-24 | Downgrade | D. Boral Capital | Buy → Hold |
| Dec-06-24 | Initiated | ROTH MKM | Buy |
| Dec-05-24 | Initiated | H.C. Wainwright | Buy |
| Sep-18-24 | Initiated | Chardan Capital Markets | Buy |
| Jul-26-24 | Initiated | Morgan Stanley | Overweight |
| Feb-15-24 | Initiated | Canaccord Genuity | Buy |
| Nov-17-20 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Mar-21-18 | Initiated | H.C. Wainwright | Buy |
View All
Cervomed Inc Stock (CRVO) Latest News
CRVO Q1 2026 Earnings: EPS Misses EstimatesProfit Margin Analysis - Newser
CRVO Q1 2026 Earnings: EPS Miss Reflects Continued Clinical InvestmentReal Trader Network - Newser
CervoMed Stock Slides Into Long Weekend as CRVO’s Cash Clock Tests Phase 3 Hopes - Bez Kabli
CervoMed Inc. (CRVO) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Modest Stock DeclineNet Profit Margin - Newser
CRVO Q1 2026 Earnings: Wider-than-Expected Loss as Pre-Clinical Stage Company Reports No RevenueEarnings Momentum Score - Newser
What CervoMed (CRVO)'s -2.75% Decline Means for Investors 2026-05-21Put Dominated - Newser
CervoMed (CRVO) Q1 2026 Results Fall Short — EPS $-0.86, Revenue $N/AAnnual Financial Report - Newser
CervoMed Inc. Announces Q1 2026 Financial Results, Corporate Updates, and Phase 3 DLB Trial Plans - Minichart
How to Value CervoMed (CRVO) After Q1 2026? EPS Not Disclosed; R - GuruFocus
CervoMed Expects EXPERTS-ALS to Dose First Patient With ALS With Neflamapimod by End of 2026 >CRVO - Moomoo
CervoMed Highlights Q1 Results and Neflamapimod Progress - TipRanks
CervoMed (NASDAQ: CRVO) posts Q1 2026 loss and cash runway into Q3 2026 - Stock Titan
CervoMed (CRVO) Reports Significant Decline in Grant Revenue and Increased Net Loss - GuruFocus
CervoMed posts smaller-than-expected Q1 net loss - TradingView
Press Release: CervoMed Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Moomoo
CervoMed announced plans to initiate a Phase III clinical trial in the second half of 2026 to evaluate the efficacy and safety of its candidate drug Neflamapimod in patients with dementia with Lewy bodies (DLB). - Bitget
Number of shareholders of CervoMed Inc. – NASDAQ:CRVO - TradingView
CervoMed Inc. Q1 2026 10-Q: Financial Results, Risk Factors, and Forward-Looking Statements Overview - Minichart
CervoMed Inc reports results for the quarter ended March 31Earnings Summary - TradingView
CervoMed Inc. 1Q 2026: Revenue $0 Net income ($7.96M), EPS ($0.86) — 10-Q Summary - TradingView
CRVO: Net loss increased to $8.0 million in Q1 2026, with cash runway concerns due to lack of new funding - TradingView
CervoMed Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
CervoMed (CRVO) widens quarterly loss and warns of going concern risk - Stock Titan
CRVO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
CRVO Stock Price, Quote & Chart | CERVOMED INC (NASDAQ:CRVO) - ChartMill
Morgan Stanley reporting units hold 8.0% of CervoMed (CRVO) in Schedule 13G/A - Stock Titan
CervoMed Inc expected to post a loss of 78 cents a shareEarnings Preview - TradingView
What CervoMed (CRVO) is doing to stay ahead (Breakdown Watch) 2026-05-08Community Momentum Stocks - newser.com
CervoMed (CRVO) outlines 2026 virtual meeting, board slate and pay plan vote - Stock Titan
[ARS] CervoMed Inc. SEC Filing - Stock Titan
CRVO Reiterated by HC Wainwright & Co. -- Price Target Maintained at $25 - GuruFocus
CRVO (CervoMed) posts wider than expected Q4 2025 loss even as shares notch mild daily gains.Crowd Risk Alerts - Newser
H.C. Wainwright Maintains CervoMed(CRVO.US) With Buy Rating, Maintains Target Price $25 - Moomoo
CRVO Maintained by D. Boral Capital -- Price Target Steady at $3 - GuruFocus
CervoMed Highlights Positive Phase 2b Neflamapimod MRI Results - TipRanks
CRVO (CervoMed Inc.) reports wider-than-expected Q4 2025 loss driven by elevated clinical research spending.Decline Phase - Cổng thông tin điện tử Tỉnh Sơn La
Neflamapimod MRI data in dementia with Lewy bodies from CervoMed (NASDAQ: CRVO) - Stock Titan
CervoMed (CRVO) Shows Promise in DLB Treatment with Neflamapimod - GuruFocus
CervoMed Announces New Data at the 2026 AAN Annual Meeting that Demonstrated Neflamapimod Increased Basal Forebrain Volume and Functional Connectivity in Dementia with Lewy Bodies - ChartMill
Drug candidate boosted brain region tied to Lewy body dementia - Stock Titan
What should investors watch for CervoMed (CRVO) stock (Smart Money Exits) 2026-04-20Public Sentiment - Cổng thông tin điện tử tỉnh Lào Cai
Is CervoMed (CRVO) stock a good candidate for diversification (Investor Concern) 2026-04-18Community Pattern Alerts - Xã Châu Thành
Operating cash flow per share of CervoMed Inc. – FWB:DP8 - TradingView — Track All Markets
CRVO Should I Buy - Intellectia AI
CRVO.O PE Ratio & Valuation, Is CRVO.O Overvalued - Intellectia AI
CRVO.O Forecast — Price Prediction for 2026. Should I Buy CRVO.O? - Intellectia AI
Buyout Rumor: Does CervoMed Inc have strong fundamentalsWeekly Stock Analysis & Verified Momentum Watchlists - baoquankhu1.vn
CRVO.O Technical Analysis & Stock Price Forecast - Intellectia AI
CRVO.O Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Lewy Body Dementia Market: Accelerating Growth And Pipeline Impact By 2034 Delveinsight Cognition Therapeutics, Keiferx, Eisai, EIP Pharma, Sun Pharma, Axovant Sciences Ltd., Cognition Therapeutics - Mena FN
Cervomed Inc Stock (CRVO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Cervomed Inc Stock (CRVO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Winton Matthew | Chief Commercial and Business |
Nov 18 '25 |
Buy |
7.95 |
1,500 |
11,925 |
15,000 |
| Gregoire Sylvie | Director |
Nov 17 '25 |
Buy |
8.46 |
10,807 |
91,427 |
12,500 |
| Gregoire Sylvie | Director |
Nov 17 '25 |
Buy |
8.46 |
10,793 |
91,309 |
1,484,078 |
| ELDER WILLIAM ROBERT | CFO, GC & Secretary |
Nov 18 '25 |
Buy |
8.32 |
2,500 |
20,800 |
12,500 |
| ELDER WILLIAM ROBERT | CFO, GC & Secretary |
Nov 17 '25 |
Buy |
8.45 |
1,000 |
8,450 |
10,000 |
| ALAM JOHN J | CEO & President |
Nov 17 '25 |
Buy |
8.46 |
10,807 |
91,427 |
1,484,078 |
| ALAM JOHN J | CEO & President |
Nov 17 '25 |
Buy |
8.46 |
10,793 |
91,309 |
12,500 |
| Gregoire Sylvie | Director |
Nov 13 '25 |
Buy |
7.51 |
4,447 |
33,397 |
1,471,578 |
| Gregoire Sylvie | Director |
Nov 14 '25 |
Buy |
7.57 |
1,707 |
12,922 |
1,473,285 |
| Gregoire Sylvie | Director |
Nov 14 '25 |
Buy |
7.55 |
1,693 |
12,782 |
1,693 |
0.98%
0.12%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):